This article was originally published in The Gray Sheet
Short list of roughly a half dozen candidates for the post of director of FDA's office of device evaluation are undergoing final interviews with center director Bruce Burlington. FDA's search committee narrowed down the list from a pool of about 50 applicants ("The Gray Sheet" July 5, In Brief). The short list of clinicians and engineers includes candidates from inside and outside the agency. A decision may be made as early as the week of Aug. 9.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.